Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 271-274

  Schultheis, Beate ^a   Nijmeijer, Bart A ^b   Yin, H ^c   Gosden, Roger G ^c   Melo, Junia V ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Chronic myeloid leukaemia; Fertility; Gonads; Imatinib; Mouse

Indexed keywords

IMATINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; LEUKEMIA; MALE; MOUSE; NONHUMAN; OVARY FOLLICLE ATRESIA; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; PRIORITY JOURNAL; SPERMATOGENESIS; TESTIS FUNCTION;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED C3H; OVARIAN FOLLICLE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SPERMATOGENESIS;

EID: 84855941960     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.025     Document Type: Article

References (33)

1. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
2. Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw 2009, 7:1050-1058.
3. Ault P., Kantarjian H., O'Brien S., Faderl S., Beran M., Rios M.B., et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006, 24:1204-1208.
4. Christopoulos C., Dimakopoulou V., Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 2008, 358:1079-1080.
5. Brougham M.F., Wallace W.H. Subfertility in children and young people treated for solid and haematological malignancies. Br J Haematol 2005, 131:143-155.
6. Tham Y.L., Sexton K., Weiss H., Elledge R., Friedman L.C., Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007, 30:126-132.
7. Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 2007, 37:190-192.
8. Hensley M.L., Ford J.M. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003, 40:21-25.
9. Seshadri T., Seymour J.F., McArthur G.A. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 2004, 351:2134-2135.
10. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139-145.
11. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100-104.
12. Yoon S.J., Kim K.H., Chung H.M., Choi D.H., Lee W.S., Cha K.Y., et al. Gene expression profiling of early follicular development in primordial, primary, and secondary follicles. Fertil Steril 2006, 85:193-203.
13. Carlsson I.B., Laitinen M.P., Scott J.E., Louhio H., Velentzis L., Tuuri T., et al. Kit ligand and c-Kit are expressed during early human ovarian follicular development and their interaction is required for the survival of follicles in long-term culture. Reproduction 2006, 131:641-649.
14. Sleer L.S., Taylor C.C. Cell-type localization of platelet-derived growth factors and receptors in the postnatal rat ovary and follicle. Biol Reprod 2007, 76:379-390.
15. Hutt K.J., McLaughlin E.A., Holland M.K. KIT/KIT ligand in mammalian oogenesis and folliculogenesis: roles in rabbit and murine ovarian follicle activation and oocyte growth. Biol Reprod 2006, 75:421-433.
16. Nilsson E.E., Detzel C., Skinner M.K. Platelet-derived growth factor modulates the primordial to primary follicle transition. Reproduction 2006, 131:1007-1015.
17. Domingues T.S., Rocha A.M., Serafini P.C. Tests for ovarian reserve: reliability and utility. Curr Opin Obstet Gynecol 2010, 22:271-276.
18. Barnes D.J., Schultheis B., Adedeji S., Melo J.V. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 2005, 24:6432-6440.
19. Faddy M.J., Telfer E., Gosden R.G. The kinetics of pre-antral follicle development in ovaries of CBA/Ca mice during the first 14 weeks of life. Cell Tissue Kinet 1987, 20:551-560.
20. Gosden R.G., Laing S.C., Felicio L.S., Nelson J.F., Finch C.E. Imminent oocyte exhaustion and reduced follicular recruitment mark the transition to acyclicity in aging C57BL/6J mice. Biol Reprod 1983, 28:255-260.
21. Schlatt S., Kim S.S., Gosden R. Spermatogenesis and steroidogenesis in mouse, hamster and monkey testicular tissue after cryopreservation and heterotopic grafting to castrated hosts. Reproduction 2002, 124:339-346.
22. Qian H., Xu J., Lalioti M.D., Gulle K., Sakkas D. Oocyte numbers in the mouse increase after treatment with 5-aminoisoquinolinone: a potent inhibitor of poly(ADP-ribosyl)ation. Biol Reprod 2010, 82:1000-1007.
23. Heartin E., Walkinshaw S., Clark R.E. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 2004, 45:1307-1308.
24. Pye S.M., Cortes J., Ault P., Hatfield A., Kantarjian H., Pilot R., et al. The effects of imatinib on pregnancy outcome. Blood 2008, 111:5505-5508.
25. Kierszenbaum A.L. Tyrosine protein kinases and spermatogenesis: truncation matters. Mol Reprod Dev 2006, 73:399-403.
26. Hutt K.J., McLaughlin E.A., Holland M.K. Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod 2006, 12:61-69.
27. Mariani S., Basciani S., Arizzi M., Spera G., Gnessi L. PDGF and the testis. Trends Endocrinol Metab 2002, 13:11-17.
28. Gonfloni S., Di T.L., Caldarola S., Cannata S.M., Klinger F.G., Di B.C., et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 2009, 15:1179-1185.
29. Conchon M., Sanabani S.S., Bendit I., Santos F.M., Serpa M., Dorliac-Llacer P.E. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 2009, 2:42.
30. Oweini H., Otrock Z.K., Mahfouz R.A., Bazarbachi A. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 2011, 283:133-134.
31. Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, Dorliac-Llacer PE, Bendit I. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010, Article ID 136252.
32. Kroll T., Ames M.B., Pruett J.A., Fenske T.S. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma 2010, 51:1751-1753.
33. O'Brien S., Berman E., Borghaei H., DeAngelo D.J., Devetten M.P., Devine S., et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2009, 7:984-1023.